 |
 Video: What is a Stock Split?
|
|
|
| Incyte is a biopharmaceutical company that develops and commercializes therapeutics. Co. has two commercialized products: JAKAFI®, for the treatment of patients with intermediate or high-risk myelofibrosis and for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea; and ICLUSIG®, a kinase inhibitor targeted for BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Co. also has rights for the development and commercialization of MGA012, an investigational monoclonal antibody that inhibits PD-1, in all indications. According to our Incyte stock split history records, Incyte has had 2 splits. | |
|
Incyte (INCY) has 2 splits in our Incyte stock split history database. The first split for INCY took place on November 10, 1997. This was a 2 for 1
split, meaning for each share of INCY owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. INCY's second split took place on September 01, 2000. This was a 2 for 1 split, meaning for each share of INCY owned pre-split, the shareholder now owned 2 shares. For example, a 2000 share position pre-split, became a 4000 share position following the split.
When a company such as Incyte splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the Incyte stock split history from start to finish, an original position size of 1000 shares would have turned into 4000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Incyte shares, starting with a $10,000 purchase of INCY, presented on a split-history-adjusted basis factoring in the complete Incyte stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
01/16/2009 |
|
| End date: |
01/15/2019 |
|
| Start price/share: |
$3.63 |
|
| End price/share: |
$78.76 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
2,069.70% |
|
| Average Annual Total Return: |
36.02% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$216,967.03 |
|
| Years: |
10.00 |
|
|
|
| Date |
Ratio |
| 11/10/1997 | 2 for 1
| | 09/01/2000 | 2 for 1 |
|
|
